The short answer: Fezolinetant (brand name Veozah) is a prescription pill for moderate to severe menopausal hot flashes (hot flushes), and it works without any estrogen (oestrogen). It blocks a receptor in the brain’s temperature-control centre, and in phase 3 trials it cut hot flash frequency and severity significantly more than placebo, with many women reaching a 50% or greater reduction (SKYLIGHT trials, The Lancet, 2023). It is not as broad as hormone therapy, which eases 30-plus symptoms, but it is a real option for women who cannot or would rather not take estrogen. The catch: the FDA added a boxed warning in December 2024 about rare but serious liver injury, so it comes with liver blood-test monitoring. Below, how it works, how well, the side effects, the cost, and how to raise it with a practitioner.

On Reddit’s menopause forums, women describe Veozah in blunt, hopeful terms. “Game changer” and “life-changer after 15 years” show up often, usually from someone who “had to try a couple of other options first.” So does the flip side: it did nothing for me, or my insurance denied it. Both are true at once, and that is exactly the honest picture worth having before you sit down with a clinician.

What is fezolinetant, and how does it stop hot flashes?

Fezolinetant is a neurokinin-3 (NK3) receptor antagonist, which is a precise way of saying it calms the specific brain cells that trigger a hot flash. It is a once-daily 45 mg tablet, non-hormonal, approved by the FDA in May 2023 as the first drug of its kind (FDA, 2023).

To understand it, you have to know the KNDy neurons. These sit in the hypothalamus, the part of the brain that acts as your body’s thermostat. During menopause, falling estrogen lets these neurons grow larger and fire harder, which flips the thermostat’s “too hot” alarm on far too easily. That misfire is the hot flash.

Fezolinetant blocks the NK3 receptor those neurons use to signal. Dial down the signal and you dial down the false alarms. This is why it targets vasomotor symptoms, the medical name for hot flashes and night sweats, without touching estrogen anywhere in the body.

That mechanism matters for who it suits. Because it never adds hormones, it sidesteps the specific reasons some women are told to avoid hormone therapy. If you want the wider view of drug-free and hormone-free routes, Yellow covers the full menu in our guide to non-hormonal menopause treatment. This post is the deep dive on this one new drug.

How well does fezolinetant work compared with placebo?

Fezolinetant clearly beats a dummy pill, and the effect holds for a year. In the phase 3 SKYLIGHT 1 and 2 trials, women averaging seven or more moderate to severe hot flashes a day took either fezolinetant or placebo (The Lancet, 2023).

The 45 mg dose significantly reduced how often and how severely hot flashes struck, at 4 weeks and 12 weeks, and those gains held through 52 weeks. In pooled analysis, a 50% or greater drop in hot flash frequency at week 12 was reached by about 23% more women on the 45 mg dose than on placebo (Menopause journal, 2024). Sleep scores improved too, which tracks with fewer night sweats waking you.

Here is the honest limit. Fezolinetant treats hot flashes and night sweats. It does not treat the 30-plus other menopause symptoms that hormone therapy can touch, such as vaginal dryness, joint aches, or the mood and brain-fog cluster. If your main complaint is flashes and sweats, that focus is fine. If your symptoms are spread wider, it is only part of the answer.

How does fezolinetant compare with HRT and antidepressants for hot flashes?

Hormone therapy remains the most effective treatment for hot flashes, and fezolinetant is a strong non-hormonal alternative for those who cannot use it. Both NICE and The Menopause Society keep HRT as first line, with non-hormonal drugs as the next step (NICE, 2026). Here is a plain comparison of the three prescription routes women weigh most.

Option	How it works	Best for	Key trade-offs
HRT (estrogen-based)	Replaces the hormones that dropped	Most menopause symptoms, not just flashes	Not suitable for some breast cancer, clot, or stroke histories
Fezolinetant (Veozah)	Blocks the NK3 brain signal behind flashes	Flashes and night sweats when estrogen is off the table	Only treats flashes and sweats. Liver monitoring required
SSRIs / SNRIs (e.g. paroxetine, venlafaxine)	Adjust brain chemistry to ease flashes	A non-hormonal option, sometimes cheaper	Modest flash relief. Own side effects like nausea

If you are weighing hormonal against non-hormonal in general, our piece on whether HRT is safe on the 2026 evidence lays out the actual risk picture rather than the headlines. And if you want to understand the symptom itself before choosing any treatment, start with what is really happening during a hot flash.

Who is fezolinetant for, and who should avoid it?

Fezolinetant is aimed at women with moderate to severe hot flashes who cannot take estrogen or would rather not. That includes many with a history of hormone-sensitive breast cancer, a history of blood clots, or those who tried HRT and could not tolerate it. NICE frames it the same way: an option when HRT is unsuitable or medically contraindicated (NICE, 2026).

It is not for everyone. It is not intended for women who can safely take HRT and get broader relief from it, and it is only studied in menopause hot flashes, not other causes of sweating.

The bigger gate is the liver. Because of the boxed warning, anyone with existing liver problems, or abnormal baseline liver blood tests, is generally steered away, and everyone needs monitoring while on it. Your practitioner will check liver bloods before you start, which is the point at which suitability is really decided.

What are the side effects of fezolinetant?

Most side effects are mild, and the serious one is rare but is why the drug carries a boxed warning. In the trials, the common complaints were headache, stomach pain, diarrhoea, trouble sleeping, and back pain, most of them mild to moderate (FDA, 2023).

The serious concern is liver injury. In December 2024 the FDA added a boxed warning, its strongest label caution, after a post-marketing case in which a woman developed significant liver injury within about 40 days of starting the drug, with fatigue, nausea, itching, yellowing of the eyes and skin, pale stools, and dark urine (FDA, 2024). Her liver tests recovered after she stopped.

To catch this early, the FDA now recommends liver blood tests before starting, then monthly for the first two months, then at months 3, 6, and 9. Stop the drug and call your practitioner straight away if you notice any of those liver warning signs. On Reddit, this is the concern women name most after cost: worth it, but the bloodwork schedule is real.

How much does fezolinetant cost, and can you get it on the NHS?

In the US, fezolinetant is expensive without help, and in the UK it is now available on the NHS in specific cases. The US list price runs around 650 US dollars a month before insurance, though the manufacturer’s savings card can bring the first month to roughly 0 dollars and later months to about 30 dollars for eligible commercially insured patients (GoodRx, 2026).

The friction women report is not the sticker price so much as prior authorisation: insurers often want proof you tried other options first, and denials are common. That is worth knowing before you get your hopes up at the pharmacy counter.

In the UK, NICE recommended fezolinetant for NHS use in March 2026 for moderate to severe hot flushes when HRT is unsuitable, for example where it is contraindicated, and estimated around 500,000 people could be eligible (NICE, 2026; British Menopause Society, 2026). HRT still stays first line for most.

Is there a newer drug like fezolinetant coming?

Yes, elinzanetant is the next-in-class option and it is already approved in the US. Sold as Lynkuet, it won FDA approval in October 2025 as the first dual neurokinin-1 and neurokinin-3 receptor antagonist, meaning it blocks two related brain signals rather than one (FDA, 2025).

In the phase 3 OASIS trials, elinzanetant reduced hot flash frequency and severity, with improvement reported as early as week 1 (Bayer / OASIS programme, 2025). It targets the same KNDy system as fezolinetant, and researchers are watching whether the dual action helps with sleep and mood alongside flashes.

For now, treat it as the emerging cousin. If fezolinetant is on your radar, it is reasonable to ask a practitioner where elinzanetant fits, especially as access and long-term data mature.

How do you bring up fezolinetant with your practitioner?

Come with your hot flash pattern and your reason for wanting a non-hormonal route, and ask directly whether fezolinetant fits. A useful opener: “My hot flashes are moderate to severe, I can’t or don’t want to take estrogen, and I’d like to know if Veozah is an option for me.”

Then work through the practical checklist together: your liver health and baseline blood tests, whether HRT was ruled out and why, what monitoring the schedule will involve, and what it will cost you after insurance or whether you qualify on the NHS.

If you do not have a menopause-literate practitioner, that is the first thing to fix. Yellow keeps a directory of practitioners who take this seriously at spotyellow.com/directory. Going in informed changes the conversation from being handed a script to making a shared decision.

Frequently Asked Questions

Does Veozah actually work, or is it a waste of money?

It works for many women but not all. In trials, a large share reached a 50% or greater cut in hot flashes, and reviewers online often call it a game changer, especially for night sweats (The Lancet, 2023). Others feel little effect. It treats only flashes and sweats, not other symptoms.

Is fezolinetant safe for the liver?

Serious liver injury is rare but real, which is why the FDA added a boxed warning in December 2024 (FDA, 2024). You get liver blood tests before starting, monthly for two months, then at months 3, 6, and 9. Stop and call your practitioner if you notice yellowing skin, dark urine, or unusual fatigue.

Can I take Veozah if I’ve had breast cancer?

Often yes, and this is one of its clearest uses. Because fezolinetant contains no estrogen, it is frequently considered for women with a history of hormone-sensitive breast cancer who are advised against HRT. Your oncologist and menopause practitioner should confirm it suits your specific history and liver health.

How is Veozah different from HRT?

HRT replaces hormones and eases 30-plus menopause symptoms, and it is still the most effective treatment for hot flashes. Fezolinetant is non-hormonal and treats only hot flashes and night sweats, by blocking a brain signal. It is the go-to when estrogen is unsuitable or unwanted, not a wider replacement for HRT.

How much does fezolinetant cost without insurance?

Around 650 US dollars a month at US list price, though the manufacturer’s savings card can cut that sharply for eligible insured patients, sometimes to about 30 dollars a month after a free first month (GoodRx, 2026). In the UK, NICE approved it for NHS use in specific cases in March 2026 (NICE, 2026).

How long until Veozah starts working?

Fairly quickly. In the SKYLIGHT trials, women saw measurable reductions in hot flash frequency and severity as early as week 1, with clear improvement by week 4 and further gains by week 12, held through a full year (The Lancet, 2023). If you notice nothing after several weeks, that is worth raising with your practitioner.

Fezolinetant (Veozah): Does the Non-Hormonal Hot Flash Drug Work, and Is It Safe?